{"id":2010,"date":"2022-09-16T21:38:55","date_gmt":"2022-09-16T18:38:55","guid":{"rendered":"https:\/\/www.sightsciences.com\/us\/?p=1485"},"modified":"2024-05-27T09:00:26","modified_gmt":"2024-05-27T06:00:26","slug":"sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-european-society-of-cataract-and-refractive-surgery-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.sightsciences.com\/us\/sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-european-society-of-cataract-and-refractive-surgery-annual-meeting\/","title":{"rendered":"Sight Sciences OMNI\u00ae Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting"},"content":{"rendered":"

Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up
\nand over 400 eyes treated in 31 centers in both combination cataract and standalone use<\/h3>\n

MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. announced today that its
\nOMNI Surgical System will be featured in seven clinical presentations at the 2022\u00a0European Society of Cataract &
\nRefractive Surgeons\u00a0(ESCRS) meeting, to be held in\u00a0Milan, Italy\u00a0on\u00a0Friday, September 16\u00a0through\u00a0Tuesday, September
\n20.
\nAt Sight Sciences Booth A22 in Hall 4 at the Milano Convention Centre, ESCRS attendees will also have the opportunity to engage in peer-to-peer discussions with four glaucoma physicians and participate in hands-on demonstrations with the OMNI Surgical System – an implant-free procedure that uniquely addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm\u2019s canal and the collector channels.<\/p>\n

\u201cGlobally, there are significant drawbacks associated with eyedrop-based glaucoma polypharmacy in terms of both cost to the healthcare system and poor patient compliance,\u201d said Paul Badawi, CEO and co-founder of Sight Sciences. He continued, \u201cWe are honored to witness the growing adoption of the OMNI Surgical System in both combination cataract procedures as well as in standalone use.\u201d<\/p>\n

Poster Presentations<\/strong><\/p>\n

    \n
  1. \n
      \n
    1. Intraocular Pressure (IOP) Fluctuations and Visual Field Status: Fluctuation Suppression with Combined
      \nCanaloplasty and Trabeculotomy in Open-Angle Glaucoma (OAG) by Michael Greenwood, MD<\/li>\n
    2. Outcomes Of Canaloplasty and Trabeculotomy in Glaucomatous Eyes with Previous Trabecular Micro-Bypass
      \nImplantation and Uncontrolled on Medication by Daniel Terveen, MD; Michael Greenwood, MD<\/li>\n
    3. A Prospective, 36-Month Evaluation of Subjects with Mild to Moderate Open-Angle Glaucoma Treated with
      \nthe OMNI Surgical System as Standalone Procedure by Karsten Klabe, MD; Andreas Fricke, MD<\/li>\n
    4. Omni Surgical System: Preliminary Results from a Systematic Review Evaluating the Treatment of
      \nOpen-Angle Glaucoma by Dan Lindfield, MD<\/li>\n
    5. Long Term Effect of Ab-Interno Canaloplasty with or without Cataract Extraction (CE) on Intraocular
      \nPressure (IOP) and Use of IOP Lowering Medications in Patients with Open-Angle Glaucoma (OAG) by Simon
      \nOndrejka, Norbert Koerber<\/li>\n
    6. Real World Evaluation of Canaloplasty and Trabeculotomy Combined with Cataract Surgery in Open-Angle
      \nGlaucoma (OAG): A Retrospective, Multicenter, 12 Month Study (ROMEO II) by James Murphy, MD<\/li>\n
    7. OMNI in Open-Angle Glaucoma Treatment: A 42-Month Interim Follow-Up by Iwona Grabska-Liberek, MD, PhD;
      \nAnna M. Koziorowska, MD; Joanna Wereszczy\u0144ska, MD; Julita Majszyk-Ionescu, MD<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n

      OMNI Experts at ESCRS (Booth A22\/Hall 4) <\/strong>
      \nFriday, September 16, 2022<\/p>\n